Loading quotes...

Forecast

The analysts' average price target is €6.60 (+2.33%). The median is €6.60 (+2.33%).

Buy	3
Hold	3
Sell	2

News Go to news feed

Coloplast A-S (spons ADRs) to release quarterly results for September 30, 2025, on November 4, 2025

Coloplast A-S (spons ADRs) will publish its quarter results for September 30, 2025, on November 4. Ten analysts expect an average EPS of $0.095 versus $0.090 in the prior year; 14 analysts forecast revenue of about $1.10 billion (+7.54% vs. $1.02 billion). For the fiscal year, 22 analysts see an average EPS of $0.330 (unchanged) and 21 analysts project annual revenue of around $4.37 billion versus $3.93 billion in the prior year. » More on finanzen.net
Coloplast reports solid Q3 and confirms annual guidance

Coloplast reported a solid Q3 with 6.6% organic sales growth and an EBIT margin of 27.5%, confirmed the annual guidance of around 7% organic growth and a 27–28% EBIT margin, and cited adverse effects from a product recall in China. Growth was strong in most business areas, but Kerecis showed slowed momentum; the company also announced a restructuring into two business divisions. The guidance takes expected recall costs and neutral currency effects into account. » More on de.investing.com
Coloplast A-S (B) publishes results for quarter ended 30 June 2025

Coloplast A-S (B) will publish on 19 August 2025 its quarterly results for the period ended 30 June 2025; analysts on average expect earnings per share of DKK 5.37 (previous year DKK 5.67) and revenue of DKK 7.04 billion (up 2.24% year on year). For the current fiscal year, 20 analysts forecast an average EPS of DKK 23.15 and revenue expectations of DKK 28.16 billion. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, COLOPLAST UN.ADR 1/10 DK1 has already paid €0.0668 in dividends. The last payout was in June.

Financials

In the last quarter, COLOPLAST UN.ADR 1/10 DK1 had revenue of €1bn and net profit of €198.97m

(EUR)	June 2026	YoY
Revenue	1bn	7.33%
Gross profit	667.95m	5.92%
Net profit	198.97m	84.40%
EBITDA	308.52m	5.83%

Fundamentals

Metric	Value
Market capitalization	€14.75bn
Number of shares	2.25bn
52-week high/low	€8.68 - €5.04
Dividend yield	4.77%
Dividends TTM	€0.31
Beta	0.53
P/E ratio	39.54
PEG ratio	-1.23
P/B ratio	8.17
P/S ratio	3.84

Company profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.